{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["2(10)"],"submitter":["Jang SB"],"pubmed_abstract":["<h4>Introduction</h4>Lazertinib is a potent, irreversible, brain-penetrant, mutant-selective, and wild-type-sparing third-generation EGFR tyrosine kinase inhibitor (TKI), creating a wide therapeutic index. Cardiovascular adverse events (AEs), including QT prolongation, decreased left ventricular ejection fraction (LVEF), and heart failure, have emerged as potential AEs with certain EGFR TKI therapies.<h4>Methods</h4>Cardiac safety of lazertinib was evaluated in TKI-tolerant adults with <i>EGFR</i> mutation-positive locally advanced or metastatic NSCLC receiving lazertinib (20-320 mg/d). QT intervals corrected with Fridericia's formula (QTcF) prolongation, time-matched concentration-QTcF relationship, change of LVEF, and cardiac failure-associated AEs were evaluated. The clinical findings w"],"journal":["JTO clinical and research reports"],"pagination":["100224"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8501499"],"repository":["biostudies-literature"],"pubmed_title":["Cardiac Safety Assessment of Lazertinib: Findings From Patients With <i>EGFR</i> Mutation-Positive Advanced NSCLC and Preclinical Studies."],"pmcid":["PMC8501499"],"pubmed_authors":["Kim SW","Ahn MJ","Haddish-Berhane N","Oh SW","Cho BC","Sim S","Han JY","Kim KB","Cho EK","Mehta J","Jang SB","Lee KH"],"additional_accession":[]},"is_claimable":false,"name":"Cardiac Safety Assessment of Lazertinib: Findings From Patients With <i>EGFR</i> Mutation-Positive Advanced NSCLC and Preclinical Studies.","description":"<h4>Introduction</h4>Lazertinib is a potent, irreversible, brain-penetrant, mutant-selective, and wild-type-sparing third-generation EGFR tyrosine kinase inhibitor (TKI), creating a wide therapeutic index. Cardiovascular adverse events (AEs), including QT prolongation, decreased left ventricular ejection fraction (LVEF), and heart failure, have emerged as potential AEs with certain EGFR TKI therapies.<h4>Methods</h4>Cardiac safety of lazertinib was evaluated in TKI-tolerant adults with <i>EGFR</i> mutation-positive locally advanced or metastatic NSCLC receiving lazertinib (20-320 mg/d). QT intervals corrected with Fridericia's formula (QTcF) prolongation, time-matched concentration-QTcF relationship, change of LVEF, and cardiac failure-associated AEs were evaluated. The clinical findings w","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Oct","modification":"2026-05-08T23:26:34.079Z","creation":"2022-02-11T12:08:49.1Z"},"accession":"S-EPMC8501499","cross_references":{"pubmed":["34647107"],"doi":["10.1016/j.jtocrr.2021.100224"]}}